STOCK TITAN

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.

Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.

The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.

Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.

Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.

This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

Can-Fite BioPharma (NYSE: CANF) announced that Dr. Kim A. Papp will present findings from the Phase III COMFORT study at the 31st EADV Congress in Milan on September 10, 2022. The study showed that Piclidenoson significantly improved psoriasis symptoms compared to placebo. Dr. Papp, a leading expert with over 150 studies, is also designing a pivotal Phase III trial for FDA and EMA submission. Can-Fite's drug candidate is positioned to address severe psoriasis, leveraging its unique mechanism of action to inhibit inflammatory cytokines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced the completion of a safety study for Piclidenoson, a treatment for canine osteoarthritis. The efficacy trial will be financed by Vetbiolix, which holds exclusive rights to Piclidenoson for two years. The global market for canine osteoarthritis is anticipated to reach $3 billion by 2028. If successful, Vetbiolix will pay Can-Fite milestone and royalty fees upon regulatory approval. Piclidenoson aims to provide a safer alternative to current NSAID treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (CANF) plans to submit registration plans for its lead drug Piclidenoson to the FDA and EMA for treating moderate to severe psoriasis. The company reported positive topline results from its Phase III COMFORT study, demonstrating significant improvement over placebo and a favorable safety profile compared to Otezla. Notably, only 1% of Piclidenoson patients experienced gastrointestinal issues, versus 6% for Otezla. The study involved over 400 patients and showed that those with higher disease severity benefited more from Piclidenoson. Can-Fite aims for strong market positioning with this candidate.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.22%
Tags
none
Rhea-AI Summary

Can-Fite BioPharma reports positive results from its Phase III COMFORT™ trial for Piclidenoson, a treatment for moderate to severe plaque psoriasis. The primary endpoint was met, with significant improvement observed in patients receiving a 3 mg dosage compared to placebo at week 16 (9.7% vs. 2.6%, P<0.04). Piclidenoson demonstrated an excellent safety profile, better than Otezla. Can-Fite plans to approach the FDA and EMA for further studies. The company holds five licensing agreements globally for Piclidenoson.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.91%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) has announced that their study on CF602, an allosteric modulator of the A3 adenosine receptor, has been published in the journal Andrologia. The study demonstrates that CF602 effectively reverses erectile dysfunction (ED) in a diabetic rat model, showing potential as an alternative treatment for the estimated 30-35% of ED patients who are non-responders to standard PDE5 inhibitors like Viagra and Cialis. The global ED market is valued at $3.6 billion and projected to grow to $5.94 billion by 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) has published an article on A3 Adenosine Receptor-targeting drugs in MDPI's journal Molecules. The data supports the potential of Piclidenoson and Namodenoson as frontrunners for FDA approval, showcasing their efficacy against psoriasis, liver cancer, and NASH. Can-Fite's extensive clinical data involves over 1,500 patients across multiple trials, with current studies including a Phase III for psoriasis and a Phase IIb for NASH. The company has received regulatory designations for its drug candidates that address significant market needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) reported its financial results for Q1 2022, with revenues of $0.20 million, up 38.5% from $0.15 million in Q1 2021. The company holds $16.5 million in cash and equivalents. R&D expenses rose 39.8% to $1.82 million due to ongoing clinical trials for psoriasis and NASH treatments. The net loss increased to $2.43 million from $1.87 million year-on-year. Upcoming milestones include Phase III psoriasis study results expected in Q2 2022 and ongoing Phase IIb and III studies for NASH and liver cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) has received a patent for its A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation, particularly in non-alcoholic steatohepatitis (NASH) and fatty liver disease. The patent is recognized in about 40 countries, including Japan and the EU. The market for NASH treatment is expected to reach $35 billion by 2025. Can-Fite is currently conducting a Phase IIb clinical trial for its drug candidate Namodenoson, which previously met key endpoints in Phase IIa trials, showing safety and efficacy in reducing liver fat.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced a Phase II study where Namodenoson, an oral drug targeting liver cancer, cleared all lesions in an advanced patient. The pivotal Phase III trial has received FDA and EMA approval and is now open to recruit around 450 hepatocellular carcinoma patients. The drug selectively binds to the A3 adenosine receptor, prevalent in cancer cells. CEO Dr. Pnina Fishman is set to present at the Adenosine Pathway Targeted Cancer Immunotherapy Summit in Boston on May 12, 2022, highlighting the drug's promising results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
conferences
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) is advancing a topical treatment for psoriasis using its Phase III oral drug candidate, Piclidenoson. Recent preclinical studies show significant efficacy in managing psoriasis symptoms. The global psoriasis drug market, valued at $11.37 billion, is projected to grow at a CAGR of 6.5%. Can-Fite expects to release topline results for its Phase III trial in Q2 2022, with positive interim data supporting the development of its topical formulation as a complement to the oral treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none

FAQ

What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is $1.48 as of December 20, 2024.

What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is approximately 8.8M.

What does Can-Fite BioPharma Ltd. specialize in?

Can-Fite BioPharma specializes in developing orally bioavailable small molecule therapeutic products for cancer, liver, and inflammatory diseases.

Where is Can-Fite BioPharma Ltd. located?

Can-Fite BioPharma Ltd. is headquartered at 10 Bareket Street, פ"ת, Israel.

What is Piclidenoson?

Piclidenoson is a drug candidate from Can-Fite BioPharma currently in Phase III clinical trials for treating psoriasis.

What is Namodenoson used for?

Namodenoson is aimed at treating liver conditions such as hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH).

What stage are the trials for Namodenoson?

Namodenoson is in a Phase III trial for HCC and a Phase IIb trial for NASH.

What is the A3 adenosine receptor (A3AR)?

The A3 adenosine receptor (A3AR) is a therapeutic target used by Can-Fite BioPharma's platform technology for drug development.

How does Can-Fite BioPharma's technology benefit patients?

Can-Fite BioPharma's technology focuses on developing oral therapeutics, which are easier to administer, potentially improving patient compliance and treatment outcomes.

What is the significance of Can-Fite BioPharma's partnerships?

Partnerships with research institutions and other entities help Can-Fite BioPharma advance its drug development programs and bring innovative therapies to market.

Is Can-Fite BioPharma listed on any stock exchange?

Yes, Can-Fite BioPharma Ltd. is listed on NASDAQ under the symbol CANF.

What is the focus of Can-Fite BioPharma's current projects?

The current focus includes advanced clinical trials for drugs treating psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH).

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares

NYSE:CANF

CANF Rankings

CANF Stock Data

8.84M
6.10M
10.5%
2.27%
Biotechnology
Healthcare
Link
United States of America
Ramat Gan